Novartis Piles Up a Week of Contrasts: A Licensing Bet, Promising MS Data, and a Clinical Setback

Novartis signs $3.2B Alteogen pact, posts positive MS trial data, but suspends CAR-T studies after deaths.

The Basel-based pharmaceutical giant has delivered a flurry of announcements that, taken together, paint a picture of a company aggressively broadening its toolkit — not just with new molecules but with delivery technologies that could reshape how existing therapies are administered.

The latest move came with the signing of a licensing and option agreement with South Korean biotech Alteogen, securing access to a subcutaneous drug delivery platform. Media reports suggest the deal could be worth up to $3.2 billion. The technology promises to convert intravenous infusions into simpler injections under the skin — a format that shortens treatment times and could improve patient adherence, a growing priority across the industry.

A Week of Clinical Headlines

The Alteogen pact lands in the middle of an unusually dense news cycle for the company. Just days earlier, Novartis unveiled positive Phase III topline results for remibrutinib in relapsing multiple sclerosis. In the REMODEL-1 and REMODEL-2 trials, the BTK inhibitor cut the annualized relapse rate compared with the established therapy teriflunomide, while also demonstrating superiority across key secondary endpoints, including the reduction of inflammatory brain lesions. A positive trend on disability progression delay was observed at three months, with a nominally significant effect at six months in a combined analysis. No liver toxicity signal emerged, according to the company.

Full data will be presented as a late-breaking abstract at the MSToronto2026 congress from October 21–23, followed by an investor call. Global regulatory submissions for remibrutinib in MS are now being prepared — a development investors view as a potential cornerstone for Novartis' neurology franchise in a market long dominated by a handful of established treatments.

The Other Side of the Coin

The same day brought darker news. On August 24, Novartis suspended eight clinical trials of its experimental cell therapy rap-cabtagene autoleucel (rap-cel) following three patient deaths linked to severe immune reactions. The halt affects only autoimmune and neurology indications — oncology studies with the CAR-T candidate remain untouched, according to Reuters.

The juxtaposition of breakthrough data and a safety scare created a telling market reaction. Shares climbed as much as 5.6 percent in early Zurich trading, with investors clearly weighing the commercial potential of remibrutinib as the more consequential program. Bloomberg confirmed the connection between the two announcements and the share price move, noting the net effect remained positive despite the setback.

A Stock in Solid Shape

The positive momentum lands on a share price that was already in good health. The stock closed Tuesday at €139.02, just 3.7 percent below its 52-week high of €144.30 reached at the end of February. Year-to-date, the shares are up 18 percent, with a 28 percent gain over twelve months. From its 52-week low of €102.40 last September, the stock has climbed 36 percent.

The elevated 30-day volatility reading of 26 percent reflects the density of market-moving news in recent weeks. The shares currently trade at €139.10, roughly 3.6 percent off the yearly peak.

Operational Backdrop

The clinical and strategic headlines sit on a solid operational foundation. Second-quarter results showed net sales rising 3 percent in US dollars to $14.4 billion, driven by Kisqali, Kesimpta, Scemblix, Pluvicto, and Leqvio. Core operating income held steady at $5.9 billion, with the margin easing 70 basis points to 41.2 percent of net sales.

The company reaffirmed its July guidance in July: low single-digit sales growth with a slight decline in core operating income at constant currencies.

Shareholder returns remain a priority. In the first half, Novartis repurchased 18.2 million of its own shares for $2.8 billion on the SIX Swiss Exchange. Of the buyback program launched in July 2025 — worth up to $10 billion — roughly $5.6 billion remains available.

A Side Note in Basel

Amid the clinical and commercial news, Novartis also confirmed an adjustment at its home base: up to 130 positions will be cut in Basel, with some activities relocated from Kleinbasel. Media reports frame this as an organizational realignment, separate from the week's clinical developments.

Investors will get another opportunity to probe the pipeline on September 3, when the company participates in a fireside chat at the Jefferies "Back to School" healthcare conference.

For now, the Alteogen deal stands as the week's clearest strategic signal: Novartis is positioning itself not merely as a drug developer but as a platform player in drug delivery — a field with the potential to generate licensing revenues and offer differentiation in an increasingly competitive landscape.